
---
title: '奥翔药业：西他沙星原料药通过CDE技术审评'
categories: 
 - 金融
 - 证券时报网
 - 快讯
headimg: 'https://picsum.photos/400/300?random=5999'
author: 证券时报网
comments: false
date: Tue, 26 Jul 2022 18:33:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=5999'
---

<div>   
<p>证券时报e公司讯，<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS603229" style="color: #2f67d1;text-decoration: none;" code="603229" target="_blank">奥翔药业</a>(603229)7月26日晚间公告，西他沙星原料药通过CDE技术审评。西他沙星是广谱喹诺酮类抗菌药，用于治疗严重难治性感染性疾病。通过CDE技术审评，表明该原料药已可销售至国内市场。</p>

                  
</div>
            